• Happy Holidays from Cafepharma! To allow its staff to spend holiday time with their families, the Cafepharma Message Boards will be switched to read-only from 6:00 PM Eastern time on Tuesday, December 24 until 10:00 PM Eastern time on Wednesday, December 25. During this time, all posts will be available for view. However, no one will be able to make new posts during this time.


Now is the time - sell your stock!

anonymous

Guest
Novo will be losing ALOT of key people soon, and Lilly is ramping up production for Mounjaro AND Zepbound way faster. 3Q and 4Q numbers will reveal a slowing/miss of # for Semaglutide products, where Lilly will exceed.
Not saying this is forever, but next 6 months could move stock down to $105-$110 range, based on P/E ratio expectations.
 






Novo will be losing ALOT of key people soon, and Lilly is ramping up production for Mounjaro AND Zepbound way faster. 3Q and 4Q numbers will reveal a slowing/miss of # for Semaglutide products, where Lilly will exceed.
Not saying this is forever, but next 6 months could move stock down to $105-$110 range, based on P/E ratio expectations.
FYI: You instantly lose all credibility when you spell “a lot” as one word; it’s every bit as egregious as not knowing the difference between “there, their & they’re”.
 






FYI: You instantly lose all credibility when you spell “a lot” as one word; it’s every bit as egregious as not knowing the difference between “there, their & they’re”.
While you focus on that minor grammatical error, the rest of us will take this sage advice and save ourselves a significant amount of money.
 






Novo will be losing ALOT of key people soon, and Lilly is ramping up production for Mounjaro AND Zepbound way faster. 3Q and 4Q numbers will reveal a slowing/miss of # for Semaglutide products, where Lilly will exceed.
Not saying this is forever, but next 6 months could move stock down to $105-$110 range, based on P/E ratio expectations.
You don’t know any “key people,” dumb rep.